ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

In Section A, individuals will receive diverse doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More members is going to be enrolled on the identified monotherapy dosign routine. In Phase B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will receive